Gene-nutrient interactions and gender may modulate the association between ApoA1 and ApoB gene polymorphisms and metabolic syndrome risk

Atherosclerosis

Volumn 214, Issue 2, 2011, Pages 408-414

  Phillips, Catherine M ^a   Goumidi, Louisa ^b   Bertrais, Sandrine ^b   Field, Martyn R ^c   McManus, Ross ^d   Hercberg, Serge ^c   Lairon, Denis ^b   Planells, Richard ^b   Roche, Helen M ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b INSERM   (France)

^c Hitachi Dublin Laboratory   (Ireland)

^d TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

Apolipoproteins; Genetic polymorphisms; Insulin sensitivity; Metabolic syndrome; Monounsaturated fatty acids

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; C REACTIVE PROTEIN; CHOLESTEROL; COMPLEMENT COMPONENT C3; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOUNSATURATED FATTY ACID; POLYUNSATURATED FATTY ACID; SATURATED FATTY ACID;

ABDOMINAL OBESITY; ADULT; ALCOHOL CONSUMPTION; ALLELE; ARTICLE; BODY MASS; CALORIC INTAKE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DYSLIPIDEMIA; FAT INTAKE; FEMALE; GENDER; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; GLUCOSE BLOOD LEVEL; HOMEOSTASIS; HOMOZYGOSITY; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NUTRITIONAL STATUS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTOLIC BLOOD PRESSURE; WAIST CIRCUMFERENCE;

EID: 79151484519     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2010.10.029     Document Type: Article

References (37)

1. Grundy SM., Cleeman J.I., Daniels S.R., et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005, 112:2735-2752.
2. Spranger J, Kroke A., Mohlig M., et al. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes 2003, 52:812-817.
3. Engstrom G., Hedblad B., Eriksson K.F., Janzon L., Lindgarde F. Complement C3 is a risk factor for the development of diabetes: a population-based cohort study. Diabetes 2005, 54:570-575.
4. Halkes C.J., van Dijk H., de Jaegere P.P., et al. Postprandial increase of complement component 3 in normolipidemic patients with coronary artery disease: effects of expanded-dose simvastatin. Arteriosclerosis, Thrombosis, and Vascular Biology 2001, 21:1526-1530.
5. van Oostrom A.J., Alipour A., Plokker T.W., Sniderman A.D., Cabezas M.C. The metabolic syndrome in relation to complement component 3 and postprandial lipemia in patients from an outpatient lipid clinic and healthy volunteers. Atherosclerosis 2007, 190:167-173.
6. Ginsberg H.N., MacCallum P.R. The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: Part I. Increased cardiovascular disease risk and the importance of atherogenic dyslipidemia in persons with the metabolic syndrome and type 2 diabetes mellitus. Journal of the Cardiometabolic Syndrome 2009, 4:113-119.
7. Lind L., Vessby B., Sundstrom J. The apolipoprotein B/AI ratio and the metabolic syndrome independently predict risk for myocardial infarction in middle-aged men. Arteriosclerosis, Thrombosis, and Vascular Biology 2006, 26:406-410.
8. Sierra-Johnson J., Romero-Corral A., Somers V.K., et al. ApoB/apoA-I ratio: an independent predictor of insulin resistance in US non-diabetic subjects. European Heart Journal 2007, 28:2637-2643.
9. Corella D., Ordovas J.M. Single nucleotide polymorphisms that influence lipid metabolism: interaction with dietary factors. Annual Review of Nutrition 2005, 25:341-390.
10. Ordovas J.M. Genetic interactions with diet influence the risk of cardiovascular disease. The American Journal of Clinical Nutrition 2006, 83:443S-446S.
11. Phillips C., Lopez-Miranda J., Perez-Jimenez F., McManus R., Roche H.M. Genetic and nutrient determinants of the metabolic syndrome. Current Opinion in Cardiology 2006, 21:185-193.
12. Phillips C.M., Goumidi L., Bertrais S., et al. Complement component 3 polymorphisms interact with polyunsaturated fatty acids to modulate risk of metabolic syndrome. The American Journal of Clinical Nutrition 2009, 90:1665-1673.
13. Phillips C.M., Goumidi L., Bertrais S., et al. Dietary saturated fat modulates the association between STAT3 polymorphisms and abdominal obesity in adults. The Journal of Nutrition 2009, 139:2011-2017.
14. Vessby B. Dietary fat, fatty acid composition in plasma and the metabolic syndrome. Current Opinion in Lipidology 2003, 14:15-19.
15. Minihane A.M, Jofre-Monseny L., Olano-Martin E., Rimbach G. ApoE genotype, cardiovascular risk and responsiveness to dietary fat manipulation. The Proceedings of the Nutrition Society 2007, 66:183-197.
16. Caslake M.J., Miles E.A., Kofler B.M., et al. Effect of sex and genotype on cardiovascular biomarker response to fish oils: the FINGEN Study. The American Journal of Clinical Nutrition 2008, 88:618-629.
17. Lopez-Miranda J., Marin C., Castro P., et al. The effect of apolipoprotein B xbaI polymorphism on plasma lipid response to dietary fat. European Journal of Clinical Investigation 2000, 30:678-684.
18. Ordovas J.M., Corella D., Cupples L.A., et al. Polyunsaturated fatty acids modulate the effects of the APOA1 G-A polymorphism on HDL-cholesterol concentrations in a sex-specific manner: the Framingham Study. The American Journal of Clinical Nutrition 2002, 75:38-46.
19. Hercberg S., Galan P., Preziosi P., et al. The SU.VI.MAX Study: a randomized, placebo-controlled trial of the health effects of antioxidant vitamins and minerals. Archives of Internal Medicine 2004, 164:2335-2342.
20. Feinberg M., Favier J.C., Ireland-Ripert J.-R. Répertoire général des aliments, Fondation Française pour la Nutrition; Centre Informatique sur la Qualité des Aliments 1991, Institut National de la Recherche Agronomique: Technique et Documentation, Lavoisier.
21. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, E., and treatment of high blood cholesterol in adults (adult treatment panel III). Journal of the American Medical Association 2001, 285:2486-2497.
22. Matthews D.R., Hosker J.P., Rudenski A.S., et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
23. Perseghin G., Caumo A., Caloni M., Testolin G., Luzi L. Incorporation of the fasting plasma FFA concentration into QUICKI improves its association with insulin sensitivity in nonobese individuals. The Journal of Clinical Endocrinology and Metabolism 2001, 86:4776-4781.
24. Liang K.Y., Zeger S.L. Regression analysis for correlated data. Annual Review of Public Health 1993, 14:43-68.
25. Lopez-Miranda J., Ordovas J.M., Espino A., et al. Influence of mutation in human apolipoprotein A-1 gene promoter on plasma LDL cholesterol response to dietary fat. Lancet 1994, 343:1246-1249.
26. Mata P., Lopez-Miranda J., Pocovi M., et al. Human apolipoprotein A-I gene promoter mutation influences plasma low density lipoprotein cholesterol response to dietary fat saturation. Atherosclerosis 1998, 137:367-376.
27. Talmud P.J., Ye S., Humphries S.E. Polymorphism in the promoter region of the apolipoprotein AI gene associated with differences in apolipoprotein AI levels: the European Atherosclerosis Research Study. Genetic Epidemiology 1994, 11:265-280.
28. Morcillo S., Cardona F., Rojo-Martinez G., et al. Association between MspI polymorphism of the APO AI gene and Type 2 diabetes mellitus. Diabetic Medicine 2005, 22:782-788.
29. Meyer K.A., Kushi L.H., Jacobs D.R., Folsom A.R. Dietary fat and incidence of type 2 diabetes in older Iowa women. Diabetes Care 2001, 24:1528-1535.
30. Storlien L.H., Baur L.A., Kriketos A.D., et al. Dietary fats and insulin action. Diabetologia 1996, 39:621-631.
31. Vessby B., Unsitupa M., Hermansen K., et al. Substituting dietary saturated for monounsaturated fat impairs insulin sensitivity in healthy men and women: the KANWU Study. Diabetologia 2001, 44:312-319.
32. Kien C.L., Bunn J.Y., Ugrasbul F. Increasing dietary palmitic acid decreases fat oxidation and daily energy expenditure. The American Journal of Clinical Nutrition 2005, 82:320-326.
33. Tierney AC, McMonagle J, Shaw DI, et al. Effects of dietary fat modification on insulin sensitivity and on other risk factors of the metabolic syndrome-LIPGENE: an European randomized dietary intervention study. International Journal of Obesity (Lond) 2010; in press.
34. Angotti E., Mele E., Costanzo F., Avvedimento E.V. A polymorphism (G→A transition) in the -78 position of the apolipoprotein A-I promoter increases transcription efficiency. The Journal of Biological Chemistry 1994, 269:17371-17374.
35. Smith J.D., Brinton E.A., Breslow J.L. Polymorphism in the human apolipoprotein A-I gene promoter region. Association of the minor allele with decreased production rate in vivo and promoter activity in vitro. The Journal of Clinical Investigation 1992, 89:1796-1800.
36. Yuan H.Y., Chiou J.J., Tseng W.H., et al. FASTSNP: an always up-to-date and extendable service for SNP function analysis and prioritization. Nucleic Acids Research 2006, 34:W635-W641.
37. Samson S.L., Wong N.C. Role of Sp1 in insulin regulation of gene expression. Journal of Molecular Endocrinology 2002, 29:265-279.